



Annual Report 2025

Our Trial Results

Clinical research
for a cure tomorrow

[swisscancerinstitute-jahresbericht.ch](https://www.swisscancerinstitute-jahresbericht.ch)

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
		Other		Geriatric Oncology in Switzerland: Results of a Nationwide Survey among Cancer Specialists in the Swiss Group for Clinical Cancer Research (SAKK) Network	Vetter M, Chiru ED, Micheloud C, Charles RP, Beyer J, Gagesch M, Gärtner J, Honecker F, Kugler H, Poudens-Gadout L, Rieder-Nicolet F, Rössler W, Schlögel M, Vollmer K, Margulies A, Dougoud-Chauvin V	ASCO	Online / Proceedings only
		Other		Geriatric Oncology in Switzerland: Results of a Nationwide Survey among Cancer Specialists in the Swiss Group for Clinical Cancer Research (SAKK) Network	Vetter M, Chiru ED, Micheloud C, Charles RP, Beyer J, Gagesch M, Gärtner J, Honecker F, Kugler H, Poudens-Gadout L, Rieder-Nicolet F, Rössler W, Schlögel M, Vollmer K, Margulies A, Dougoud-Chauvin V	ESMO	Poster
Breast Cancers		Intergroup	IBCSG 48-14 POSITIVE	5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial	Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni MA, Saura Manich C, Shimizu C, Satersdal A, Kroep JR, Warner E, Mailliez A, Amant F, Ferreiro T, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH	ESMO	Oral presentation
Breast Cancers		Intergroup	SOFT, TEXT	15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.	Francis P, Fleming G, Pagani O, Walley B, Loi S, Colleoni M, Regan M	ASCO	Oral presentation
Breast Cancers	Surgery	Secondary	SAKK 23/16	Nodal disease burden in patients with clinically node-positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting: pre-planned TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)	Weber WP, Tausch CT, Hayoz S, Matrai Z, Xepapadakis G, Simonson C, Bjelic-Radacic V, Lam GT, Montagna G, Gnant M, Rosenberger LH, de Bree E, Satler R, Fehr M, Leo C, Lelievre L, Bucher S, Schmid S, Exner R, Reisenberger K, Beckmann U, Muenst S, Henke G, Zwahlen DR, Ruhstaller T, Ribl K, Urban C, Crown A, Lee JE, Boileau J, Williams AD, Jonghan Y, DiNome ML, Poultzidi A, Gonzales E, Wong SM, Schulz A, Nealeigh M, Ahn SG, Botty van den Bruele AM, Chae BJ, Mueller A, Hagen D, Ryu JM, Savolt A, Kurzeder C, Heil J, Egle D, Heidinger M, Knauer M	SABCS	Oral presentation
Cancers of Head and Neck		Intergroup	EORTC PROLoNg	EORTC 2014-HNCG PROLoNg: Pembrolizumab and radiotherapy for oligometastatic squamous cell carcinoma of the head and neck, randomized phase III trial	Braña I, Machiels JP, Nevens D, Oliva Bernal M, Hernando Calvo M, Licitra LFL, Bossi P, Cabezas-Camarero S, Espeli VG, Bonomo P, Franzese C, Ost P, Zimmermann F, Reynaert N, Granada R, Govaerts AS, Clementel E, Vivancos A, Balermipas P	ESMO	Poster
Developmental Therapeutics	Breast Cancers	Primary	SAKK 65/16	TLD-1, a novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase 1 study (SAKK 65/16)	Joerger M, Klose M, Colombo I, Koster K, Gobat K, Haefliger S, Rabaglio M, Bastian S, Schwitler M, Eckhardt K, Hayoz S, Halbherr S, Sessa C, Michelet R, McLaughlin AM, Hess D, Kloft C, Stathis A	ESMO TAT	Poster

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Developmental Therapeutics	Urogenital Cancers	Primary	SAKK 67/20	Open-label dose escalation phase 1b trial of a new micellar docetaxel compound in patients with metastatic castration-resistant prostate cancer (mCRPC), SAKK 67/20.	Colombo I, Rietveld P, Fischer S, Merlo S, Vogl U, Cathomas R, Koolen S, Zoelly D, Gobat K, Eckhardt K, Sessa C, Stathis A, Aurelius Omrin, Joerger M	ESMO TAT	Poster
Developmental Therapeutics	Breast Cancers	Secondary	SAKK 65/16	TLD-1, a Second-Generation Nano-Liposomal Doxorubicin, in Patients with Advanced Breast Cancer from the Dose Escalation and Expansion Phase 1 Study (SAKK 65/16)	Rabaglio-Poretti M, Koster KL, Gobat K, Haefliger S, Colombo I, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Halbherr S, Thürlimann B, Sessa C, Stathis A, Hess D, Joerger M	SGBCC	Poster
Developmental Therapeutics	Breast Cancers	Secondary	SAKK 66/22	Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Controlled Trial	Zürner-Härdi U, Müller A, Tredan O, Micheloud C, Musilova J, Bender L, Joerger M, Schmid T, Rossi L, Schwitter M, Vetter M, Niemeyer M, Witzel I, Patsouris A, Martin Babau J, Deleuze A, Robert M	SABCS	Poster
Gastrointestinal Cancers		Meta-analysis	SAKK 75/08	Recurrence-free survival as a surrogate endpoint for overall survival in resectable esophageal cancer: An individual patient data analysis of phase III RCTs	Okui Y, Matsuda S, Nagashima K, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven B P L, Tsushima T, Takeuchi H, Kato K, Kitagawa Y	ASCO	Poster
Gastrointestinal Cancers		Meta-analysis	SAKK 75/08	Surrogacy between pathological complete response and overall survival: An individual patient data analysis of eight RCTs on neoadjuvant treatment plus surgery for esophageal cancer	Okui Y, Matsuda S, Nagashima K, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven B P L, Tsushima T, Takeuchi H, Kato K, Kitagawa Y	ASCO GI	Poster
Gynecological Cancers		Intergroup	ENGOT-en7_ AtTend	Final overall survival (OS) results from the randomized double-blind phase III AtTend/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer	Barretina-Ginesta MP, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Roh JW, Rabaglio M, Marmé F, Piovano E, Leitner K, Fariñas Madrid L, Takehara K, Allan K, Lee YC, Zamagni C, Pardo Búrdalo B, Tasca G, Ferrero A, Colombo N	ESMO	Oral presentation
Gynecological Cancers		Intergroup	ENGOT-en7_ AtTend	WES-derived aneuploidy score (W-AS) identifies MMRd patients with reduced benefit from immunotherapy in endometrial cancer: Multi-omic analysis of the phase III AtTend/ENGOT-EN7 trial	Mazzarella L, Colombo N, Harano K, Rulli E, Antill Y, Hudson E, Kim YM, Heitz F, Rabaglio M, Piovano E, Cueva Banuelos J, Takehara K, Lombard J, Allan K, Tasca G, Bignotti E, Uggeri S, Frige G, Barberis M, Barretina Ginestre V	ESMO	Oral presentation
Gynecological Cancers		Secondary	SAKK_OvCaR	The SAKK OvCaR Registry: First Interim Analysis of a Multicenter Swiss Ovarian Cancer Registry (OvCaR)	Colombo I, Heubner ML, Schar S, Wyss S, Heinzelmann-Schwarz V, Hasler-Strub U, Siegenthaler F, Labidi-Galy I, Ciliberti E, Nerone M, Blum V, Fehr M, Zanetti Dällenbach R, Uhlmann Nussbaum C, Meili G, Nay Fellay C, Brambs C, Passmann-Kegel H, Sessa C, Vetter M	SOHC	Poster

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Leukemias		Intergroup	CLL18	CLL18/MOIRAI trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in treatment-naive CLL/SLL	Cramer P, Al-Sawaf O, Görgen E, Mazot L, Robrecht S, Schüler-Aparicio M, Paulitschek C, Zey A, Albrecht A, Blau J, Jung L, Reidel S, Bosch F, da Cuna Bang C, Doubek M, Feyzi E, Fink A, Ghia P, Gregor M, Guieze R, Jamroziak K, Janssens A, Kater AP, Kersting S, Langerbeins P, Levin M, Lindström V, Mattsson M, Niemann C, Quinquenel A, Ritgen M, Scarfò L, Staber P, Stilgenbauer S, Tadmor T, Thornton P, Tausch E, Ysebaert L, Fischer K, Eichhorst BF, Hallek M	ICML	Oral presentation
Leukemias		Intergroup	CLL13	The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive CLL	Fürstenau M, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber P, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin M, da Cunha-Bang C, Schneider C, Herishanu Y, O'Shea D, Baumann M, Widmer A, Nösslinger T, Poulsen CB, Frederiksen H, Lotfi K, Ranti J, Enggard L, Velders G, Vekemans M, de Heer K, Snijders TF, Siemes C, Wendtner C, Knauf W, Kröber A, Zahn M, Illmer T, Schöttker B, Simon F, Fink A, Fischer K, Holmes E, Kreuzer K, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Kater AP, Eichhorst BF	ICML	Oral presentation
Leukemias		Intergroup	CLL13	The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: final analysis from the phase 3 GAlA/CLL13 trial	Fürstenau M, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber P, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin M, da Cunha-Bang C, Schneider C, Herishanu Y, O'Shea D, Baumann M, Widmer A, Nösslinger T, Poulsen CB, Frederiksen H, Lotfi K, Ranti J, Enggard L, Velders G, Vekemans M, de Heer K, Snijders TF, Siemes C, Wendtner C, Knauf W, Kröber A, Zahn M, Illmer T, Schöttker B, Simon F, Fink A, Fischer K, Holmes E, Kreuzer K, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Kater AP, Eichhorst BF	EHA	Oral presentation
Leukemias		SCI services		Prognostic impact of the AML60+ score for patients with acute myeloid leukemia treated with hypomethylating agents	Petermichl V, Fuchs S, Weber M, Gobat K, Graf L, Gerth Y, Lehmann T, Driessen C, Mey U, Cathomas R, Cogliatti S, Silzle T	EHA	Poster
Leukemias		SCI services		Prognostic significance of the AML60+ score for non-intensively treated patients with acute myeloid leukemia	Petermichl V, Fuchs S, Weber M, Gobat K, Graf L, Gerth Y, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T	DGHO	Poster

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Leukemias		SCI services		The Glasgow Prognostic Score adds Prognostic Information in Elderly AML Patients Ineligible for Intensive Treatment Independently from the Molecular RiskProfile – a Retrospective Multicentre Analysis	Fuchs S, Petermichl V, Weber M, Micheloud C, Graf L, Gerth Y, Goede J S, Lehmann T, Driessen C, Mey U, Cathomas R, Cogliatti S, Silzle T	SOHC	Poster
Lung Cancers		Intergroup	ACHILES	Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).	Gronberg BH, Aanerud M, Dumoulin DW, Nyman J, Schytte T, Bjaanæs MM, Neumann K, Tsakonas G, Kastelijn EA, Helbekkmo N, Langer SW, Rothschild S, Appenzeller C, Stigt J, McCulloch T, Sorger H, Sandvei MS, Killingberg KT, Frøseth TC, Halvorsen TO	ASCO	Oral presentation
Lung Cancers		Intergroup	ETOP ADOPT	ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with resectable NSCLC	Schmid S, Dimopoulou G, van Schil PE, König D, Mauti LA, Itchins M, Frueh M, Popat S, Pérol M, Landi L, Oselin K, Aigner C, Forde PM, De Jong W, Roschitzki-Voser H, Ruepp B, Grolimund E, Dafni U, Stahel RA, Peters S	ESMO	Poster
Lung Cancers		Intergroup	ETOP ADOPT	ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC	Schmid S, Dimopoulou G, Van Schil PE, Finn SP, Solomon B, Popat S, Perol M, Landi L, Oselin K, Aigner A, Roschitzki-Voser H, Grolimund E, Ruepp B, Dafni U, Stahel RA, Peters S	ELCC	Poster
Lung Cancers		Intergroup	ETOP AMAZE	Amivantamab, lazertinib and bevacizumab in EGFR-mutant advanced NSCLC with acquired resistance to 3rd generation EGFR-TKI: Final results from the phase II ETOP AMAZE-lung trial	Soo RA, Popat S, Dellaporta T, De Langen AJ, Nadal E, Iranzo Gomez P, Frueh M, Perol M, Metro G, Gonzalez ASG, Salamero MC, Cerciello FW, Addeo A, Roschitzki-Voser H, Ruepp B, Gasca A, Dafni U, Peters S, Stahel RA	ELCC	Poster
Lung Cancers	Developmental Therapeutics	Primary	SAKK 17/18	SAKK 17/18 ORIGIN trial: Efficacy and safety from a multicentre phase II trial of gemcitabine and atezolizumab in patients with advanced pleural mesothelioma progressing on chemotherapy or immune checkpoint inhibitors	Curioni-Fontecedro A, Rigutto A, Früh M, Rothschild S, Addeo A, Britschgi C, Waibel C, Cerciello F, von Briel T, Hayoz S, Somasundaram V, Musilova J, Schär S, Viode A, Shichkova P, Bruderer R, Feng Y, Nguyen D L, Zellweger C, von Moos R, Joerger M	ELCC	Poster
Lung Cancers		SCI services		Molecular subtypes and their correlation to clinical outcomes in a real-world analysis of patients with extensive disease small cell lung cancer (ED-SCLC) treated with first-line chemo-immunotherapy	Zellweger N, Schmid S, Alborelli I, Losmanová T, Früh M, Bertschinger M, Waibel C, Cerciello F, Frösch P, Mark M, Bettini A, Häuptle P, Blum V, Hayoz S, Gobat K, Rothschild SI, Mauti L, Prince SS	ELCC	Poster

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Lung Cancers		SCI services		Molecular subtypes and their correlation to clinical outcomes in a real-world analysis of patients with extensive stage small cell lung cancer (ES-SCLC) treated with first-line chemo-immunotherapy	Zellweger N, Schmid S, Alborelli I, Losmanova T, Früh M, Bertschinger M, Waibel C, Cerciello F, Froesch P, Mark M, Bettini A, Häuptle P, Blum V, Hayoz S, Gobat K, Mauti LA, Savic Prince S, Rothschild SI	DGHO	Oral presentation
Lung Cancers		SCI services		Prognostic Impact of PD-L1 Expression in a Swiss Cohort of Patients with EGFR-Mutant Non-Small Cell Lung Cancer Treated with First Line Osimertinib	Schuler A, Schär S, Schmid S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Froesch P, Pankovics J, Mark MT, Rothschild SI, Addeo A, Janthur WD, Siano M, Huser J, Boos L, Britschgi C, Früh M	WCLC	Poster discussion
Lung Cancers		SCI services		SLFN11 Expression as Potential Prognostic Marker in Pleural Mesothelioma	Losmanová T, Gross L, Gobat K, Koster K, Rothschild SI, Boos LA, Frehner L, Almeida SC, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Früh M, Mauti LA, Schmid S	ESMO	Poster
Lung Cancers		Secondary	SAKK 16/14	Perioperative Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer – Final analysis of the multicenter single-arm phase II trial SAKK 16/14	Rothschild S I, Zippelius A, Hayoz A, Chiquet S, Savic Prince S, Bettini A, Frueh M, Joerger M, Lardinois D, Gelpke H, Opitz I, Britschgi C, Mauti L A, Peters S, Mark M, Cathomas R, Ochsenbein A F, Janthur W-D, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Gonzalez M, M. Pless	ELCC	Oral presentation
Lung Cancers		Secondary	SAKK 16/14	Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy (SAKK 16/14)	Rothschild S, Da Silva Y, Chang D, Benecke L, Pfaffl M, Hayoz S, Bettini A, Frueh M, Mauti L, Britschgi C, Peters S, Mark M, Ochsenbein A, Janthur WD, Mach N, Waibel C, Froesch P, Zippelius A, Pless M, Muller L	SOHC	Oral presentation
Lung Cancers		Secondary	SAKK 16/14	Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy in the trial SAKK 16/14	Rothschild S, Da Silva Y, Chang D, Benecke L, Pfaffl M, Hayoz S, Bettini A, Frueh M, Mauti L, Britschgi C, Peters S, Mark M, Ochsenbein A, Janthur WD, Mach N, Waibel C, Froesch P, Zippelius A, Pless M, Muller L	ESMO	Poster
Lung Cancers		Secondary	SAKK 16/14	Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy in the trial SAKK 16/14	Rothschild S, Da Silva Y, Chang D, Benecke L, Pfaffl M, Hayoz S, Bettini A, Frueh M, Mauti L, Britschgi C, Peters S, Mark M, Ochsenbein A, Janthur WD, Mach N, Waibel C, Froesch P, Zippelius A, Pless M, Muller L	DGHO	Oral presentation

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Lung Cancers	Developmental Therapeutics	Secondary	SAKK 17/18	Comprehensive plasma profiling in NSCLC patients undergoing IO- and chemotherapy identifies potential proteomic signatures for progression-free survival	Rigutto A, Schaefer S, Shichkova P, Raess L, Arthur Viodé A, Below C, Treiber T, Bruderer R, Joerger M, Musilova J, Hayoz S, Somasundaram V, Nuñez N, Fournier N, Lourenço J, Gottardo R, Becher B, Addeo A, Gupta A, Feng Y, Curioni-Fontecedro A	AACR	Poster
Lung Cancers	Developmental Therapeutics	Secondary	SAKK 17/18	Mapping microbiome and immune cell interactions in patients with advanced NSCLC	Heeb L, Rigutto A, Joerger M, Hayoz S, Derosa L, Gupta A, Curioni-Fontecedro A	ESMO IO	Poster
Lymphomas		Intergroup	EMCL-Registry	Radiotherapy in Patients with Advanced Stage Mantle Cell Lymphoma achieves Durable Local Tumor Control- A SAKK/GLA/EMCL Real-World-Analysis from the EMCL-Registry	Simon L, Drabke S, Tilch M, Herold S, Pott C, Gomes da Silva M, Silkenstedt E, Melchardt T, Aydilek E, Renner C, Vucinic V, von der Heyde E, Tometten M, Kerkhoff A, Fehr M, Hofstra E, Kubin TW, Wille K, Heine A, Leng C, Christofyllakis K, Ahlborn M, Kohl I, Hecker JS, Hansmann L, Müller F, Bisping G, von Bonin M, Reinhardt C, Alig S, Schmidberger H, Hess G	ICML	Poster
Lymphomas		Intergroup	TRIANGLE	Evaluation of established prognostic markers in younger mantle cell lymphoma patients under ibrutinib containing regimens - An Analysis Embedded in the MULTIPLY Project	Gutmair K, Reinke S, Beà S, Campo E, Ladetto M, Doorduyn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Dreyling M, Klapper W, Hoster E	ICML	Poster
Lymphomas		Intergroup	TRIANGLE	Ibrutinib added to MCL treatment has strong impact on MRD response and disease kinetics: results from the TRIANGLE trial	Khouja M, Jurinovic V, Ferrero S, Genuardi E, Kehden B, Civita AM, Niemann CU, García Sanz R, Herrera AM, Homburg C, Verhagen OJ, Velden VH, Kubetzko S, Fronkova E, Gameiro P, Schmidt C, Doorduyn JK, Gine E, Jerkemann M, Hutchings M, Walewski J, Riise J, Mey UJ, Trneny M, Vergote VK, Shpilberg O, Gomes da Silva M, Leppä S, Unterhalt M, Klapper W, Hoster E, Dreyling M, Ladetto M, Pott M	ICML	Oral presentation
Lymphomas		Intergroup	TRIANGLE	Impact of IGH Repertoire after Ibrutinib-Containing Regimens in Younger untreated MCL Patients: An Analysis of the TRIANGLE Data Embedded in the MULTIPLY Project	Ragaini S, Moia R, Gutmair K, Khouja M, Genuardi E, Nabki J, Nakov P, Drandi D, Homburg CH, Garcia-Sanz R, Gameiro P, Fronková E, Schaefer B, Montana C, Al Deeban B, Stilgenbauer S, Niemann CU, Celli M, Doorduyn J, Gaidano G, Giné E, Gomes da Silva M, Klener P, Jerkeman M, Mey U, Hoster E, Evangelista A, Beà S, Dreyling M, Ferrero S, Pott C, Ladetto M	ICML	Poster

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Lymphomas		Secondary	SAKK 38/19	Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma	Salehi M, Piffaretti D, Romano I, Marquez de Almeida J, Javanmard Khameneh H, Moia R, Bruscaggin A, Jauk F, Bocchetta S, Condoluci A, Forestieri G, Piroso MC, Terzi di Bergamo L, Schär S, Zenobi A, Stathis A, Monticelli S, Gaidano G, Guarda G, Rossi D	14a Giornata della ricerca e dell'Innovazione in Medicina Umana della Svizzera Italiana	Oral presentation
Lymphomas		Secondary	SAKK 38/19	Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma	Piffaretti D, Romano I, Marquez de Almeida J, Salehi M, Khameneh H, Moia R, Bruscaggin A, Jauk F, Bocchetta S, Condoluci A, Forestieri G, Piroso MC, Terzi di Bergamo L, Schär S, Stathis A, Monticelli S, Gaidano G, Guarda G, Rossi D	ICML	Oral presentation
Lymphomas		Secondary	SAKK 38/19	Feasibility of ctDNA and PET guided therapy in untreated DLBCL. Preliminary results of the SAKK 38/19 phase II trial	Stathis A, Bruscaggin A, Hitz F, Fischer N, Gritti G, Novak U, Mey U, Zenz T, Schär S, Lang N, Zander T, Schmidt A, Rhyner G, Cairoli A, Gaidano G, Hohaus S, Piroso MC, Ballova V, O'Meara Stern A, Mingrone W, Mamot C, Fehr M, Musilova J, Bertoni F, Hayoz S, Zucca E, Dirnhofer S, Ceriani L, Rossi D	ICML	Oral presentation
Lymphomas		Secondary	SAKK 38/19	Feasibility of ctDNA and PET guided therapy in untreated DLBCL. preliminary results of the SAKK 38/19 phase II trial	Stathis A, Bruscaggin A, Hitz F, Fischer N, Gritti G, Mey U, Zenz T, Schaer S, Lang N, Zander T, Schmidt A, Rhyner G, Cairoli A, Gaidano G, Hohaus S, Piroso MC, Ballova V, O'Meara Stern A, Mingrone W, Mamot C, Fehr M, Musilova J, Bertoni F, Hayoz S, Zucca E, Dirnhofer S, Novak U, Ceriani L, Rossi D	SOHC	Oral presentation
Sarcomas		Secondary	SAKK 57/24	SAKK 57/24 –Feasibility of Total Neoadjuvant Treatment with HYPeRthermia in patients with high-risk extremity and trunk soft tissue sarcoma (TNT-HYPE). A multicenter, single arm, open label, phase II trial	Kollar A, Lindner L, Dietrich D, Riesterer O, Zilli T, Krasniqi F, Bankel L, Appenzeller C, Zacharia R, Stutz E	CTOS	Poster
Urogenital Cancers		Intergroup	EORTC DE-ESCALATE	EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in meta-static hormone-naïve prostate cancer in the era of new AR pathway inhibitors	Grisay G, Turco F, Patrikidou, A, Gallardo E, McDermott R, Coens C, Fournier B, Gillissen S, Tombal B	ESMO	Poster
Urogenital Cancers		Intergroup	STAMPEDE	On-treatment serum prostate specific antigen (PSA) and metastatic burden at treatment start: landmark analysis of 7129 patients starting long-term androgen deprivation (ADT) and randomised in the STAMPEDE platform protocol	Kayani M, Murphy L, Dutey-Magni P, Howlett S, Padden-Modi M, Abdel-Aty H, Brown L C, Amos C, Chan K, Gilbert D, Langley R, Sachdeva A, Brown M, Sydes R M, Varughese M, Gillissen S, Clarke N W, Parmar M K B, James N D, Attard G	ESMO	Poster

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Urogenital Cancers		Meta-analysis	SAKK 09/10	Gene signature predictor of dose-response to prostate radiation: validation of PORTOS in phase III trials	Zhao S G, Ryu H M, Proudfoot J A, Davicioni E, Michalski J M, Spratt D E, Hayoz S, Simko J P, Sandler H M, Pollack A, Parliament M B, Dayes O S, Correa R J M, Karrison T G, Hall W A, Aebersold D M, Feng F Y, Ghadjar P, Tran P T, Dal Pra A	ASCO GU	Oral presentation
Urogenital Cancers		Secondary	SAKK 01/10	Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: long-term follow-up from the international multicenter phase II trial SAKK 01/10	Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold DM, Putora P-M, Berthold D, Zihler D, Zengerling F, Dieing A, Mueller A-C, Schaer C, Biaggi C, Gillessen S, Cathomas R	ESMO	Oral presentation
Urogenital Cancers		Secondary	SAKK 01/10	Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: long-term follow-up from the international multicenter phase II trial SAKK 01/10	Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold DM, Putora P-M, Berthold D, Zihler D, Zengerling F, Dieing A, Mueller A-C, Schaer C, Biaggi C, Gillessen S, Cathomas R	SOHC	Oral presentation
Urogenital Cancers		Secondary	SAKK 06/17	Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): final analysis of the single arm phase II trial SAKK 06/17	Cathomas R, Rothschild SI, Hayoz S, Spahn M, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Musilova J, Petrausch U	ESMO	Poster
Urogenital Cancers		Secondary	SAKK 06/17	Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): final analysis of the single arm phase II trial SAKK 06/17	Cathomas R, Rothschild SI, Hayoz S, Spahn M, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Musilova J, Petrausch U	SOHC	Oral presentation
Urogenital Cancers		Secondary	SAKK 06/19	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): interim analysis of SAKK 06/19 study	Cathomas R, Hayoz S, Rentsch CA, Niederberger P, Stenner F, Hirschi A, Vogl U, Lorch A, Spahn M, Tsantoulis P, Stefanie Aeppli S, Erdmann A, Strebel RT, Fischer Maranta A, Fankhauser C, Chiquet S, Rothschild SI, Petrausch U	ESMO	Poster
Urogenital Cancers		Secondary	SAKK 06/19	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): interim analysis of SAKK 06/19 study	Cathomas R, Hayoz S, Rentsch CA, Niederberger P, Stenner F, Hirschi A, Vogl U, Lorch A, Spahn M, Tsantoulis P, Stefanie Aeppli S, Erdmann A, Strebel RT, Fischer Maranta A, Fankhauser C, Chiquet S, Rothschild SI, Petrausch U	SOHC	Oral presentation
Urogenital Cancers		Secondary	SAKK 08/23	Addition of Darolutamide to First Line Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Randomized Open Label Phase II Trial (SAKK 08/23)	Vogl U, Eckhardt K, Gobat K, Gillessen S, Cathomas R	ASCO GU	Poster

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Conference	Type of Presentation
Urogenital Cancers		Secondary	SAKK 09/10	Long-term urinary continence recovery and influencing factors after salvage radiotherapy: Results of the SAKK 0910 dose escalation trial	Schröder C, Zwahlen DR, Schär S, Bernhard J, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Beck M, Thalmann GN, Aebbersold DM, Ghadjar P	ESTRO	Oral presentation
Urogenital Cancers	Breast Cancers	Secondary	SAKK 96/12	Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)	Templeton AJ, Hayoz S, Wyss-Neyer S, Cathomas R, Pereira Mestre R, Rothermundt C, Anchisi S, Ackermann CJ, Reichel K, Mueller B, Egger C, Pedrazzini A, Popescu RA, Züllig L, Woelky R, Bützberger P, Schmid F, Von Moos R, Gillessen S	ASCO GU	Poster